{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:10:18Z","timestamp":1791670218143,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Progression from paroxysmal to persistent atrial fibrillation (AF) is linked to adverse clinical outcomes. The present study sought to clarify whether angiotensin receptor-neprilysin inhibitor (ARNI) can delay AF progression. A retrospective cohort study was conducted on consecutive patients with paroxysmal AF admitted at the Second Affiliated Hospital of Nanchang University between January 2017 and January 2022. The risk of AF progression from paroxysmal to persistent was compared between paroxysmal patients treated with ARNI and those who received an angiotensin receptor blocker (ARB). Seven-day Holter monitoring was performed to identify persistent AF. Propensity-score matched analysis was performed to compare the two groups. Cox-regression was used to estimate the hazard ratio (HR) for AF progression events. A total of 1083 patients were screened, and 113 patients in the ARB group and 57 patients in the ARNI group were eligible for analysis. Before propensity-score matching, the ARNI therapy was associated with a lower risk of AF progression than the ARB therapy (HR 0.34; 95% confidence interval [CI] 0.14\u20130.81; P\u2009=\u20090.015) after a median follow-up of 705 (interquartile range [IQR] 512 to 895) days. Among 170 patients, 47 ARNI-treated patients were successfully matched to 47 ARB-treated patients. After a median follow-up of 724 (541\u2013929) days, compared to ARB, ARNI significantly reduced the risk of AF progression (HR 0.32; 95% CI 0.12\u20130.88; P\u2009=\u20090.016). ARNI may be superior to ARB in reducing the risk of progression from paroxysmal to persistent AF.<\/jats:p>","DOI":"10.1038\/s41598-023-30349-w","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T11:03:18Z","timestamp":1677150198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Angiotensin receptor-neprilysin inhibitor delays progression from paroxysmal to persistent atrial fibrillation"],"prefix":"10.1038","volume":"13","author":[{"given":"Youzheng","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zirong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanbing","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juxiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"30349_CR1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks, G. et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the esc. Eur. Heart. J. 42, 373\u2013498 (2021).","journal-title":"Eur. Heart. J."},{"key":"30349_CR2","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00392-017-1123-0","volume":"106","author":"H Deng","year":"2017","unstructured":"Deng, H. et al. Clinical scores for outcomes of rhythm control or arrhythmia progression in patients with atrial fibrillation: A systematic review. Clin. Res. Cardiol. 106, 813\u2013823 (2017).","journal-title":"Clin. Res. Cardiol."},{"key":"30349_CR3","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/europace\/euy222","volume":"21","author":"JP Piccini","year":"2019","unstructured":"Piccini, J. P. et al. Atrial fibrillation burden, progression, and the risk of death: A case-crossover analysis in patients with cardiac implantable electronic devices. Europace 21, 404\u2013413 (2019).","journal-title":"Europace"},{"key":"30349_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.754499","volume":"8","author":"D Pascual-Figal","year":"2021","unstructured":"Pascual-Figal, D. et al. Sacubitril-valsartan, clinical benefits and related mechanisms of action in heart failure with reduced ejection fraction: A review. Front. Cardiovasc. Med. 8, 754499 (2021).","journal-title":"Front. Cardiovasc. Med."},{"key":"30349_CR5","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/0091270009343932","volume":"50","author":"J Gu","year":"2010","unstructured":"Gu, J. et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNI). J. Clin. Pharmacol. 50, 401\u2013414 (2010).","journal-title":"J. Clin. Pharmacol."},{"key":"30349_CR6","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ Mcmurray","year":"2014","unstructured":"Mcmurray, J. J. et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371, 993\u20131004 (2014).","journal-title":"N. Engl. J. Med."},{"key":"30349_CR7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/jch.13437","volume":"21","author":"Y Huo","year":"2019","unstructured":"Huo, Y. et al. Efficacy and safety of sacubitril\/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double-blind, 8-week study. J. Clin. Hypertens 21, 67\u201376 (2019).","journal-title":"J. Clin. Hypertens"},{"key":"30349_CR8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/jch.13153","volume":"20","author":"DG Cheung","year":"2018","unstructured":"Cheung, D. G. et al. Efficacy and safety of sacubitril\/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study. J. Clin. Hypertens. 20, 150\u2013158 (2018).","journal-title":"J. Clin. Hypertens."},{"key":"30349_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.21037\/cdt-21-386","volume":"12","author":"Y Dong","year":"2022","unstructured":"Dong, Y. et al. Comparing the efficacy of angiotensin receptor-neprilysin inhibitor and enalapril in acute anterior STEMI patients after primary percutaneous coronary intervention: A prospective randomized trial. Cardiovasc. Diagn. Ther. 12, 42\u201354 (2022).","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"30349_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.amjcard.2020.12.037","volume":"143","author":"A Rezq","year":"2021","unstructured":"Rezq, A., Saad, M. & El, N. M. Comparison of the efficacy and safety of sacubitril\/valsartan versus ramipril in patients with ST-segment elevation myocardial infarction. Am. J. Cardiol. 143, 7\u201313 (2021).","journal-title":"Am. J. Cardiol."},{"key":"30349_CR11","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1002\/ehf2.13644","volume":"8","author":"J She","year":"2021","unstructured":"She, J. et al. ARNI versus ACEI\/ARB in reducing cardiovascular outcomes after myocardial infarction. ESC. Heart. Fail. 8, 4607\u20134616 (2021).","journal-title":"ESC. Heart. Fail."},{"key":"30349_CR12","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1253\/circj.CJ-21-0691","volume":"86","author":"H Ogawa","year":"2022","unstructured":"Ogawa, H. & Akao, M. Is progression from paroxysmal to sustained atrial fibrillation bad news?. Circ. J. 86, 176\u2013181 (2022).","journal-title":"Circ. J."},{"key":"30349_CR13","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jacc.2009.11.040","volume":"55","author":"CB de Vos","year":"2010","unstructured":"de Vos, C. B. et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J. Am. Coll. Cardiol. 55, 725\u2013731 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"30349_CR14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ahj.2004.09.053","volume":"149","author":"CR Kerr","year":"2005","unstructured":"Kerr, C. R. et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian registry of atrial fibrillation. Am. Heart. J. 149, 489\u2013496 (2005).","journal-title":"Am. Heart. J."},{"key":"30349_CR15","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa2104508","volume":"385","author":"MA Pfeffer","year":"2021","unstructured":"Pfeffer, M. A. et al. Angiotensin receptor-neprilysin inhibition in acute myocardial infarction. N. Engl. J. Med. 385, 1845\u20131855 (2021).","journal-title":"N. Engl. J. Med."},{"key":"30349_CR16","first-page":"1","volume":"1","author":"Q Wang","year":"2022","unstructured":"Wang, Q. et al. Sacubitril\/valsartan can reduce atrial fibrillation recurrence after catheter ablation in patients with persistent atrial fibrillation. Cardiovasc. Drugs. Ther. 1, 1\u201312 (2022).","journal-title":"Cardiovasc. Drugs. Ther."},{"key":"30349_CR17","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1002\/ehf2.13937","volume":"9","author":"L Yang","year":"2022","unstructured":"Yang, L., Zhang, M., Hao, Z., Wang, N. & Zhang, M. Sacubitril\/valsartan attenuates atrial structural remodelling in atrial fibrillation patients. ESC. Heart. Fail. 9, 2428\u20132434 (2022).","journal-title":"ESC. Heart. Fail."},{"key":"30349_CR18","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCRESAHA.114.302226","volume":"114","author":"J Heijman","year":"2014","unstructured":"Heijman, J., Voigt, N., Nattel, S. & Dobrev, D. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ. Res. 114, 1483\u20131499 (2014).","journal-title":"Circ. Res."},{"key":"30349_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/CIRCRESAHA.120.316363","volume":"127","author":"S Nattel","year":"2020","unstructured":"Nattel, S., Heijman, J., Zhou, L. & Dobrev, D. Molecular basis of atrial fibrillation pathophysiology and therapy: A translational perspective. Circ. Res. 127, 51\u2013722 (2020).","journal-title":"Circ. Res."},{"key":"30349_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/j.1540-8167.2008.01339.x","volume":"20","author":"S Zellerhoff","year":"2009","unstructured":"Zellerhoff, S. et al. Atrial arrhythmias in long-QT syndrome under daily life conditions: A nested case control study. J. Cardiovasc. Electrophysiol. 20, 401\u2013407 (2009).","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"30349_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/cvr\/cvr166","volume":"92","author":"MD Lemoine","year":"2011","unstructured":"Lemoine, M. D. et al. Arrhythmogenic left atrial cellular electrophysiology in a murine genetic long QT syndrome model. Cardiovasc. Res. 92, 67\u201374 (2011).","journal-title":"Cardiovasc. Res."},{"key":"30349_CR22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1146\/annurev-physiol-020911-153308","volume":"76","author":"DM Bers","year":"2014","unstructured":"Bers, D. M. Cardiac sarcoplasmic reticulum calcium leak: Basis and roles in cardiac dysfunction. Annu. Rev. Physiol. 76, 107\u2013127 (2014).","journal-title":"Annu. Rev. Physiol."},{"key":"30349_CR23","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s10557-021-07174-2","volume":"35","author":"WH Cheng","year":"2021","unstructured":"Cheng, W. H. et al. Effects of angiotensin receptor-neprilysin inhibitor in arrhythmogenicity following left atrial appendage closure in an animal model. Cardiovasc. Drugs. Ther. 35, 759\u2013768 (2021).","journal-title":"Cardiovasc. Drugs. Ther."},{"key":"30349_CR24","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.cardfail.2020.03.007","volume":"26","author":"PC Chang","year":"2020","unstructured":"Chang, P. C. et al. Sacubitril\/valsartan therapy ameliorates ventricular tachyarrhythmia inducibility in a rabbit myocardial infarction model. J. Card. Fail. 26, 527\u2013537 (2020).","journal-title":"J. Card. Fail."},{"key":"30349_CR25","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrd3682","volume":"11","author":"D Dobrev","year":"2012","unstructured":"Dobrev, D., Carlsson, L. & Nattel, S. Novel molecular targets for atrial fibrillation therapy. Nat. Rev. Drug. Discov. 11, 275\u2013291 (2012).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"30349_CR26","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1161\/01.CIR.0000145659.80212.6A","volume":"110","author":"T Christ","year":"2004","unstructured":"Christ, T. et al. L-type Ca2+ current downregulation in chronic human atrial fibrillation is associated with increased activity of protein phosphatases. Circulation 110, 2651\u20132657 (2004).","journal-title":"Circulation"},{"key":"30349_CR27","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1161\/CIRCEP.110.954636","volume":"3","author":"N Voigt","year":"2010","unstructured":"Voigt, N. et al. Left-to-right atrial inward rectifier potassium current gradients in patients with paroxysmal versus chronic atrial fibrillation. Circ. Arrhythm. Electrophysiol. 3, 472\u2013480 (2010).","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"30349_CR28","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1016\/j.jacc.2010.02.028","volume":"55","author":"R Caballero","year":"2010","unstructured":"Caballero, R. et al. In humans, chronic atrial fibrillation decreases the transient outward current and ultrarapid component of the delayed rectifier current differentially on each atria and increases the slow component of the delayed rectifier current in both. J. Am. Coll. Cardiol. 55, 2346\u20132354 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"30349_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173120","volume":"881","author":"LY Li","year":"2020","unstructured":"Li, L. Y. et al. Sacubitril\/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation. Eur. J. Pharmacol. 881, 173120 (2020).","journal-title":"Eur. J. Pharmacol."},{"key":"30349_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cardiores.2003.08.014","volume":"60","author":"S Cardin","year":"2003","unstructured":"Cardin, S. et al. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: Angiotensin-dependent and -independent pathways. Cardiovasc. Res. 60, 315\u2013325 (2003).","journal-title":"Cardiovasc. Res."},{"key":"30349_CR31","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/FJC.0b013e3182073c78","volume":"57","author":"AY Tan","year":"2011","unstructured":"Tan, A. Y. & Zimetbaum, P. Atrial fibrillation and atrial fibrosis. J. Cardiovasc. Pharmacol. 57, 625\u2013629 (2011).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"30349_CR32","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12265-021-10137-5","volume":"15","author":"SN Li","year":"2022","unstructured":"Li, S. N. et al. Sacubitril\/valsartan decreases atrial fibrillation susceptibility by inhibiting angiotensin ii-induced atrial fibrosis through p-smad2\/3, p-jnk, and p-p38 signaling pathways. J. Cardiovasc. Transl. Res. 15, 131\u2013142 (2022).","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"30349_CR33","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1001\/jama.2019.12843","volume":"322","author":"AS Desai","year":"2019","unstructured":"Desai, A. S. et al. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: A randomized clinical trial. JAMA 322, 1077\u20131084 (2019).","journal-title":"JAMA"},{"key":"30349_CR34","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/eurheartj\/eht099","volume":"36","author":"N Venteclef","year":"2015","unstructured":"Venteclef, N. et al. Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines. Eur. Heart. J. 36, 795\u2013805 (2015).","journal-title":"Eur. Heart. J."},{"key":"30349_CR35","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1161\/01.CIR.0000034511.06350.DF","volume":"106","author":"C Rocken","year":"2002","unstructured":"Rocken, C. et al. Atrial amyloidosis: An arrhythmogenic substrate for persistent atrial fibrillation. Circulation 106, 2091\u20132097 (2002).","journal-title":"Circulation"},{"key":"30349_CR36","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1111\/jch.13652","volume":"21","author":"K Kario","year":"2019","unstructured":"Kario, K. et al. Expert panel consensus recommendations for ambulatory blood pressure monitoring in Asia: The HOPE Asia network. J. Clin. Hypertens. 21, 1250\u20131283 (2019).","journal-title":"J. Clin. Hypertens."},{"key":"30349_CR37","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.cardfail.2017.04.014","volume":"23","author":"CW Yancy","year":"2017","unstructured":"Yancy, C. W. et al. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the heart failure society of America. J. Card. Fail. 23, 628\u2013651 (2017).","journal-title":"J. Card. Fail."},{"key":"30349_CR38","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin, P. C. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat. Med. 28, 3083\u20133107 (2009).","journal-title":"Stat. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-30349-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-30349-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-30349-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T15:48:58Z","timestamp":1701964138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-30349-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["30349"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-30349-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,23]]},"assertion":[{"value":"4 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3140"}}